Methods of treatment for myeloid leukemia

A method of modulating cancer progression and development, comprising administering to a subject a therapeutically effective amount of one or more compositions including a tyrosine kinase inhibitor, gabapentin or derivatives thereof, and rapamycin or derivatives thereof, or a pharmaceutically acceptable salt or a prodrug of one or more of the tyrosine kinase inhibitor, gabapentin or derivatives thereof, and rapamycin or derivatives thereof, wherein the one or more compositions interrupts a branched-chain amino acid transamination pathway.

A method of treating myeloid leukemia in a subject, comprising:

• administering to a subject a therapeutically effective amount of each of a tyrosine kinase inhibitor, gabapentin or derivatives thereof, and rapamycin or derivatives thereof, or a pharmaceutically acceptable salt or a prodrug of one or more of the tyrosine kinase inhibitor, gabapentin or derivatives thereof, and rapamycin or derivatives thereof.

(canceled)

A pharmaceutical composition comprising a therapeutically effective amount of a composition including a tyrosine kinase inhibitor, gabapentin or derivatives thereof, and rapamycin or derivatives thereof, or a pharmaceutically acceptable salt or a prodrug of one or more of the tyrosine kinase inhibitor, gabapentin or derivatives thereof, and rapamycin or derivatives thereof, and a pharmaceutically acceptable carrier.